UBS raised the firm’s price target on United Therapeutics (UTHR) to $705 from $655 and keeps a Buy rating on the shares. United Therapeutics remains a top pick due to several near-to-medium term catalysts, including potential upside from upcoming Idiopathic Pulmonary Fibrosis clinical trial data expected in late March/early April, where positive results and a fast approval or accelerated launch could drive momentum, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $560 from $500 at Argus
- United Therapeutics price target raised to $668 from $640 at Jefferies
- United Therapeutics price target raised to $615 from $600 at Leerink
- United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook
- United Therapeutics says phase 3 ADVANCE OUTCOMES study met its primary endpoint